← Back to Clinical Trials
Recruiting Phase 2 NCT07118618

Probenecid Administration for Alcohol Craving and Consumption

Trial Parameters

Condition Alcohol Use Disorder (AUD)
Sponsor Brown University
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 120
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2026-03-14
Completion 2030-12-31
Interventions
Probenecid Oral TabletPlacebo Oral Tablet

Brief Summary

This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g /day) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.

Eligibility Criteria

Inclusion Criteria: * • Male or female, ≥18 years. * women \>7 drinks/week; men \>14 drinks/week. * meet moderate to severe AUD score for DSM-5 criteria. * Breath Alcohol Content (BrAC)=0.00 at each visit. * in good health as confirmed by medical history, physical examination and lab tests. * willing to adhere to the study procedures. * understand informed consent and questionnaires in English at an 8th grade level. Exclusion Criteria: * • Women who are breastfeeding or positive urine test for pregnancy. * clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin \>150% of the upper normal limit, ALT/AST \>300% the UNL, creatinine clearance ≤60 dl/min * meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses * medications that reduce alcohol consumption (naltrexone, disulfiram). * use aspirin (salicylates may reduce effect of probenecid), penicillin, methotrexate (may increase concentration). *

Related Trials